JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

JNJ

185.98

-0.83%↓

ABT

124.47

-1.58%↓

TMO

559.3

+0.47%↑

ISRG

536.38

-1.44%↓

DHR

214.38

-1.22%↓

Search

Fate Therapeutics Inc

Open

SectorHealthcare

1.32 -11.41

Overview

Share price change

24h

Current

Min

1.32

Max

1.5

Key metrics

By Trading Economics

Income

3.6M

-34M

Sales

278K

1.9M

Profit margin

-1,786.576

Employees

181

EBITDA

979K

-37M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+185.16% upside

Dividends

By Dow Jones

Next Earnings

10 lis 2025

Market Stats

By TradingEconomics

Market Cap

71M

179M

Previous open

12.73

Previous close

1.32

News Sentiment

By Acuity

31%

69%

88 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 paź 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 paź 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 paź 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 paź 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 paź 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 paź 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 paź 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 paź 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 paź 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 paź 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 paź 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 paź 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 paź 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 paź 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 paź 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 paź 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 paź 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 paź 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 paź 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 paź 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 paź 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 paź 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 paź 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 paź 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 paź 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 paź 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

185.16% upside

12 Months Forecast

Average 4.42 USD  185.16%

High 7 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

4

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

88 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat